Cargando…

Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer

Immunotherapy is being tested intensively in clinical trials for prostate cancer; it includes immune checkpoint inhibition, prostate specific antigen (PSA) vaccines and dendritic cell-based strategies. Despite increasing evidence for clinical responses, the consensus of multiple trials is that prost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bryant, Geoffrey, Wang, Lin, Mulholland, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536030/ https://www.ncbi.nlm.nih.gov/pubmed/28714919 http://dx.doi.org/10.3390/ijms18071542

Ejemplares similares

Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances
por: Movassaghi, Miyad, et al.
Publicado: (2021)

Tumor-intrinsic oncogene pathways mediating immune avoidance
por: Spranger, Stefani, et al.
Publicado: (2015)

Immune mediators in the tumor microenvironment of prostate cancer
por: Dai, Jinlu, et al.
Publicado: (2017)

The tumor microenvironment and immune responses in prostate cancer patients
por: Kwon, J T W, et al.
Publicado: (2021)

Overcoming MET-mediated resistance in oncogene-driven NSCLC
por: Reischmann, Nadine, et al.
Publicado: (2023)

A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer
por: Sooi, Kenneth, et al.
Publicado: (2023)

Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer
por: Mulvey, Arthur, et al.
Publicado: (2022)

Overcoming tumor immune evasion with an unique arbovirus
por: Lyday, Bruce, et al.
Publicado: (2015)

Oncogenes, Proto-Oncogenes, and Lineage Restriction of Cancer Stem Cells
por: Brown, Geoffrey
Publicado: (2021)

Erratum: Overcoming immune resistance with radiation therapy in prostate cancer
Publicado: (2023)

Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2022)

Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling
por: Nguyen, Kim Bich, et al.
Publicado: (2019)

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
por: Osipov, Arsen, et al.
Publicado: (2019)

Overcoming docetaxel resistance in prostate cancer: a perspective review
por: Hwang, Clara
Publicado: (2012)

Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing
por: Bahmad, Hisham F., et al.
Publicado: (2022)

A CINful way to overcome addiction: how chromosomal instability enables cancer to overcome its oncogene addiction
por: Bronder, Daniel, et al.
Publicado: (2020)

Oncogenic Long Noncoding RNAs in Prostate Cancer, Osteosarcoma, and Metastasis
por: Al-Shehri, Aishah, et al.
Publicado: (2023)

Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy
por: Deng, Kaili, et al.
Publicado: (2022)

Overcoming Immune Evasion in Melanoma
por: Eddy, Kevinn, et al.
Publicado: (2020)

B lymphoma Moloney murine leukemia virus insertion region 1: an oncogenic mediator in prostate cancer
por: Liu, Qipeng, et al.
Publicado: (2019)

Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance
por: Xie, Chen, et al.
Publicado: (2021)

Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer
por: Advani, Rahul, et al.
Publicado: (2023)

SIRT3: Oncogene and Tumor Suppressor in Cancer
por: Torrens-Mas, Margalida, et al.
Publicado: (2017)

Oncogenic activation of ERG: A predominant mechanism in prostate cancer
por: Sreenath, Taduru L, et al.
Publicado: (2011)

Influence of oncogenic transcription factors on chromatin conformation and implications in prostate cancer
por: Yang, Yeqing Angela, et al.
Publicado: (2014)

Oncogenes and the Origins of Leukemias
por: Brown, Geoffrey
Publicado: (2022)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

The RARγ Oncogene: An Achilles Heel for Some Cancers
por: Brown, Geoffrey, et al.
Publicado: (2021)

The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
por: Retecki, Kuba, et al.
Publicado: (2021)

Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer
por: Kumar, Binod, et al.
Publicado: (2018)

Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment
por: Cheng, Bisheng, et al.
Publicado: (2023)

Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors
por: Einstein, David J., et al.
Publicado: (2021)

New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
por: Westover, David, et al.
Publicado: (2015)

FOXP2 confers oncogenic effects in prostate cancer
por: Zhu, Xiaoquan, et al.
Publicado: (2023)

LOSS OF THE TUMOR SUPPRESSOR, TP53, ENHANCES THE ANDROGEN RECEPTOR MEDIATED ONCOGENIC TRANSFORMATION AND TUMOR DEVELOPMENT IN THE MOUSE PROSTATE
por: He, Yongfeng, et al.
Publicado: (2019)

The long tail of oncogenic drivers in prostate cancer
por: Armenia, Joshua, et al.
Publicado: (2018)

Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer
por: Navarro-Ocón, Alba, et al.
Publicado: (2022)

The Tumor Immune Contexture of Prostate Cancer
por: Vitkin, Natasha, et al.
Publicado: (2019)

Role of tumor-associated immune cells in prostate cancer: angel or devil?
por: Wu, Shui-Qing, et al.
Publicado: (2019)

Impact of Immune Cells in the Tumor Microenvironment of Prostate Cancer Metastasis
por: Messex, Justin K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1aaoqai4rr7oti0jljv0hpmcco